Medexus Pharmaceuticals, Inc. (MDP) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BioSyent, Inc.

Fennec Pharmaceuticals, Inc.

Medexus Pharmaceuticals, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Defence Therapeutics Inc

Arch Biopartners, Inc.

Cybin, Inc.

Mindset Pharma, Inc.

Why is Medexus Pharmaceuticals, Inc. ?

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 81.75%, its profits have fallen by -108.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Medexus Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Medexus Pharmaceuticals, Inc.

85.35%

1.62

45.12%

S&P/TSX 60

29.63%

2.33

12.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.37%

EBIT Growth (5y)

0.43%

EBIT to Interest (avg)

0.91

Debt to EBITDA (avg)

2.04

Net Debt to Equity (avg)

0.25

Sales to Capital Employed (avg)

1.38

Tax Ratio

5.61%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.03%

ROCE (avg)

10.34%

ROE (avg)

4.69%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.88

EV to EBIT

35.24

EV to EBITDA

8.35

EV to Capital Employed

1.73

EV to Sales

1.07

PEG Ratio

Dividend Yield

ROCE (Latest)

4.92%

ROE (Latest)

-1.22%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

PRE-TAX PROFIT(Q)

At CAD 0.87 MM has Grown at 126.79%

NET PROFIT(Q)

At CAD 1.33 MM has Grown at 144.86%

RAW MATERIAL COST(Y)

Fallen by -8.75% (YoY

-11What is not working for the Company

NET PROFIT(9M)

At CAD 2.03 MM has Grown at -35.32%

ROCE(HY)

Lowest at -4.57%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.3 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

NET SALES(Q)

Lowest at CAD 33.82 MM

OPERATING PROFIT(Q)

Lowest at CAD 1.69 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 5.01 %

EPS(Q)

Lowest at CAD -0.11

Here's what is working for Medexus Pharmaceuticals, Inc.

Pre-Tax Profit

At CAD 0.87 MM has Grown at 126.79%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CAD MM)

Net Profit

At CAD 1.33 MM has Grown at 144.86%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Raw Material Cost

Fallen by -8.75% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Medexus Pharmaceuticals, Inc.

Inventory Turnover Ratio

Lowest at 1.3 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Net Sales

Lowest at CAD 33.82 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CAD MM)

Operating Profit

Lowest at CAD 1.69 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CAD MM)

Operating Profit Margin

Lowest at 5.01 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

EPS

Lowest at CAD -0.11

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CAD)

Debtors Turnover Ratio

Lowest at 0 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio